| Jul 29 |
Lipella stock soars 200% on Phase 2 study initiation
|
| Jul 29 |
Lipella Pharmaceuticals Initiates Phase 2a Trial for LP-310 in Oral Lichen Planus, Enrolls First Patients
|
| May 31 |
Lipella Pharmaceuticals Announces Completion of Site Initiation Visit for Phase 2a Trial of LP-310 in Oral Lichen Planus
|
| May 29 |
Lipella Pharmaceuticals Announces Abstract Publication at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
|
| May 21 |
Following Guidance from U.S. Food & Drug Administration in Type-C Meeting Lipella Pharmaceuticals to Advance Lead Product Candidate to Phase 2b
|
| May 16 |
Clearside Biomedical And 3 Other Penny Stocks Insiders Are Buying
|
| May 13 |
Lipella Pharmaceuticals First Quarter 2024 Earnings: US$0.16 loss per share (vs US$0.19 loss in 1Q 2023)
|
